Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.78 |
| ▸ | PGK1 | P00558 | 1/20 | 0.50 |
| ▸ | PGK2 | P07205 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.40 |
| ▸ | TET3 | O43151 | 2/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 1/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL27765779 | 1.00 | OR51E2 (0.78) | OR51E2PGK1PGK2SMN1; SMN2TET2 | |
| Phosphoric Acid SCHEMBL1462678 | 1.00 | OR51E2 (0.78) | OR51E2PGK1PGK2SMN1; SMN2TET2 | |
| SCHEMBL29597490 | 0.88 | — | — | |
| SCHEMBL1765577 | 0.88 | OR51E2 (1.00) | OR51E2PGK1PGK2SMN1; SMN2TET2 | |
| Water SCHEMBL10757023 | 0.88 | — | — | |
| SCHEMBL29278852 | 0.88 | OR51E2 (1.00) | OR51E2PGK1PGK2SMN1; SMN2TET2 | |
| SCHEMBL2905876 | 0.88 | — | — | |
| SCHEMBL38462 | 0.88 | — | — | |
| Water SCHEMBL21753470 | 0.88 | — | — | |
| SCHEMBL584528 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110622179-A | Platform and system for digital personalized medicine | 科格诺亚公司 | 2019-12-27 | — | — | CN | claimed |
| CN-103399098-B | Evaluation method for rat model of heart-Qi deficiency syndrome | CAO HONGXIN | 2015-06-17 | — | — | CN | claimed |
| CN-103399098-A | Evaluation method for rat model of heart-Qi deficiency syndrome | CAO HONGXIN | 2013-11-20 | — | — | CN | claimed |
| EP-0123037-B1 | PROCESS FOR PREPARING AN ADHESIVE, PREFERABLY FOR GLUEING TOGETHER CELLULOSE-CONTAINING MATERIALS AND TEXTILES | Nyugatmagyarorszagi Fagazdasagi Kombinat (HU) | 1988-04-20 | — | — | EP | claimed |
| US-20260002180-A1 | PLATFORM FOR BIO-BASED PRODUCTION OF HIGH LEVELS OF O-PHOSPHOSERINE, CYSTEATE, OR TAURINE | NATÁUR INC. (US) | 2026-01-01 | — | — | US | disclosed |
| CN-117205298-A | Compositions and methods for preventing and treating mitochondrial myopathy | 康德生物医疗有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-108508168-B | Combined sensitivity-determining marker for anticancer agent | 学校法人庆应义塾 | 2021-08-17 | — | — | CN | disclosed |
| CN-111454916-A | Novel application of glyceraldehyde-3-phosphate dehydrogenase protein or immune fragment thereof | 王泽宋 | 2020-07-28 | — | — | CN | disclosed |
| CN-111198270-A | Kit for detecting glyceraldehyde-3-phosphate dehydrogenase magnetic particle chemiluminescence and preparation method thereof | 山东泽济生物科技有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-111198271-A | Chemiluminescent enzyme-linked immunosorbent assay kit for glyceraldehyde-3-phosphate dehydrogenase detection | 山东泽济生物科技有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-110622179-A | Platform and system for digital personalized medicine | 科格诺亚公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-110545805-A | Method for inhibiting cell glycolysis process and application | QIN CAIDONG | 2019-12-06 | — | — | CN | disclosed |
| WO-2010051527-A2 | ENGINEERED MICROORGANISMS CAPABLE OF PRODUCING TARGET COMPOUNDS UNDER ANAEROBIC CONDITIONS | GEVO, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
| WO-2009134439-A2 | GROUP SPECIFIC INTERNAL STANDARD TECHNOLOGY (GSIST) FOR SIMULTANEOUS IDENTIFICATION AND QUANTIFICATION OF SMALL MOLECULES | PURDUE RESEARCH FOUNDATION (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2007-02-22 | — | — | US | disclosed |
| US-6165500-A | Preparation for the application of agents in mini-droplets | IDEA AG (DE) | 2000-12-26 | — | — | US | disclosed |
| US-5254572-A | Administering pyridoxal or precursor | VESTA MEDICINES (PTY) LTD. (ZA) | 1993-10-19 | — | — | US | disclosed |
| EP-0130030-B1 | DIAGNOSTIC APPLICATIONS OF PHOSPHOFRUCTOKINASE | Nakamura, Kunie (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4710460-A | DETECTING ENZYMEINHIBITOR PRESENT IN MALIGNANT NEOPLASMS FROM HUMAN SERUMS | NAKAMURA KUNIE (JP) | 1987-12-01 | — | — | US | disclosed |
| EP-0130030-A1 | Diagnostic applications of phosphofructokinase | Nakamura, Kunie (JP) | 1985-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002180-A1 | PLATFORM FOR BIO-BASED PRODUCTION OF HIGH LEVELS OF O-PHOSPHOSERINE, CYSTEATE, OR TAURINE | UROD, DDC, CBS | OR51E2 3079/4885PGK1 249/4885PGK2 244/4885 |
| US-20070042030-A1 | Preparation for the application of agents in mini-droplets | FABP4, NPC1L1, LIPA | OR51E2 3357/4885PGK1 3003/4885PGK2 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.